Drug Delivery and Material Science Solutions

Forward Looking Statements & Non-GAAP Financial Measures

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor

provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are

based on management’s beliefs and assumptions in light of information currently available to management. Accordingly, the

Company’s actual results may differ materially from those expressed or implied in such forward-looking statements due to

known or unknown risks and uncertainties that exist in the Company’s operations and business environment, including,

among other factors, those described in documents filed by the Company with the Securities and Exchange Commission,

specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such

statements to reflect new events, information or circumstances after the date of this presentation.

During the course of this presentation, certain non-GAAP financial information will be presented.

A reconciliation of those numbers to GAAP financial measures is available on the company’s website at www.aptar.com on

the Investor’s page (click on Events & Presentations / Presentations).

2

Overview

3

SALES BY REGION

55%32%

7%

6%

ATTRACTIVE END MARKETS

SERVING BEST KNOWN GLOBAL &

LOCAL BRANDS

DIVERSIFIED PORTFOLIO

RESEARCH AND IP-DRIVEN

Company Snapshot

1,250Patent Families

Approximately3%R & D

Of Annual Revenue

THE LEADER IN CONSUMER

DISPENSING AND DRUG DELIVERY

75-year history of innovation

Providing brand differentiation and

consumer / patient convenience

Consistent long-term focus, stability

and financial results

“We transform ideas into solutions that transform lives.”

$2.9 bil*

4

*2019 Annual Revenue

Relying on Aptar Solutions Through the Pandemic

5

Rescue drugs and

treatments

Preventive medicines

and diagnostics

Pharma

Beauty + Home

Food + Beverage

Vaccines and

therapeutics

6

Synergistic Benefits of Shared Technology, Infrastructure and Material Science Across Three Reporting Segments

6* - LTM = Last twelve months ending September 30, 2020; the EBITDA %’s of LTM values are calculated on total Segment Adjusted EBITDA and exclude Corporate Expenses

Common Technologies and Solutions… …Serving Three Market-facing Reporting Segments

Core Manufacturing Technologies1

Best-in-Class Products and Services2

Aimed at Global Megatrends3

Precision Injection Molding

High-Speed Assembly

Metal Processing + Decorating

Material Science

Dispensing and Delivery

Sealing

Active Solutions

✓ Sustainability

✓ Health + Wellness

✓ Connectivity

✓ Urbanization

✓ Changing Demographics

✓ e-Commerce/Individualization

% of Total LTM* Sales % of Total LTM* EBITDA

41%

45%

14%

68%

21%

11%

35%

EBITDA

Margin

10%

EBITDA

Margin

17%

EBITDA

Margin

$1.2 bil

$1.3 bil

$0.4 bil

$418 mil

$131 mil

$65 mil

Best in Class Healthcare Businesses – Aptar Pharma

7

$1.2BSales*

35%Adj. EBITDA Margin*

7.5%10-year CAGR

Organic Sales**

* - LTM = Last twelve months ending September 30, 2020; ** - 2009 - 2019

14GMP Facilities

(U.S., Europe, Asia and Latin

America)

• Global leader in proprietary niche drug delivery devices:

– nasal, pulmonary and ophthalmic

• Consistent long-term performance

– organic revenue growth 6-10% per year

– EBITDA margins of 32-36%

• Focused on chronic disease management and

emergency response

• Focused on key indications: allergic rhinitis, congestion,

asthma, COPD, diabetes, CNS and pain

• Over 3 decades of experience working with regulators

• Growing position in elastomeric stoppers and

components for syringes and injection devices

• Growing material science solutions group

750Patent Families

Fast Growing, High-margin Drug Delivery Franchise

8

Aptar Pharma Snapshot

9

SALES BY REGION (2020)

66%29%

2%

3%

NICHE MARKETS (2020)

45%

23%

20%

12% Prescription

Consumer HealthCare

Injectables

Active MaterialSolutions

CUSTOMERS (Approx. 1500)

INNOVATIVE SOLUTIONS

IP / PATENTS

DECADES OF PATIENT /

CONSUMER EXPERIENCE

8 BillionOver

Solutions per Year

Branded Rx / Generics / OTC

750Patent Families

Not a Contract Manufacturer

Managing close to

Successful long-term track record with over

150 approved NDAs, ANDAs and INDs in

past five years

9

Leader in Delivery Systems for Focused Therapies

10

Nasal Delivery Solutions Eye Care Delivery Solutions Pulmonary Delivery Solutions

Global leader in nasal devices for Allergic Rhinitis,

Aptar Pharma delivers across a wide spectrum of

nasal needs, from respiratory and allergy

treatments to vaccines and crisis medications.

Global leader in pressurized metered dose inhaler

(pMDI) valves. We address the Asthma and COPD

therapy markets with a broad range of devices

including pMDI valves, Dry Powder Inhalers

(DPIs), and electronic and connected devices.

Our Ophthalmic Squeeze Dispenser is the

leading device for preservative-free multidose

prescription medications and OTC eye care

products with over 250 references on the market.

Growth from Conversion to Nasal Format

Naloxone HCl Nasal Spray used for the emergency

treatment of a known or suspected opioid

overdose.

Rescue treatments delivered with our nasal

devices can be administered quickly and easily

without the need for professional training.

Pharmaceutical and biotech companies continue to

seek better ways to administer their medicines.

Emergent Bio’s NARCAN®

11

Aptar’s Unidose Nasal Spray Device

Other CNS Drugs Recently Repurposed for New Delivery Formats

Bidose Nasal Spray Device Unidose Nasal Spray Devices

Protective Active Container and

Unidose Nasal Powder Device

12

Anti-depressant Therapy Hypoglycemic Crisis Treatment Epilepsy Seizure Treatments

Growing in the Injectables Market

13

Proven injectables partner

• 550+ customers in 70+ countries

worldwide

• Working with all of the top 10

Pharma players in injectables

• 70 of the 100 top molecules,

mostly life saving treatments

COVID-19 Opportunities

• > 100 injectable vaccines /

antiviral treatments being explored

• Increase in emergency / antibiotics

treatments

• QuickStart™ turnkey solution for

clinical development

Added-value solutions to meet most

stringent market requirements

around the development of complex

& highly sensitive drug formulations

• PremiumCoat™

• Premium Fill®

• Premium Vision™

Global manufacturing network

expansion to meet fast

growing demand

Expanding the Moat with Broad Pharma Services Platform

14

Support through every step of the drug development journey

Guiding you through every step of drug product development

Device &

formulation

development

Clinical trialsRegulatory

filings

Market launch &

post-launch

A global leader in

patient onboarding

and adherence

programs.

A leading provider of

orally inhaled &

nasal drug product

design & development

services.

A full-service cGMP

lab specializing in

analytical testing of

drug delivery

systems.

A full-service cGMP lab

providing industry-

leading particulate

detection & predictive

analytical services.

A global provider of

innovative

drug delivery

systems and service

solutions.

Aptar Pharma Services

Digital Integrator with Connected Devices as Foundation

15

Supports the digital therapeutic ecosystem

Guiding you through every step of drug product development

Device & app

development

Clinical trial

adherence

monitoring

Patient

adherence

monitoring

Digital analytics

Patient

management

software for

healthcare providers

(India)

A leading provider of

digital services to

asthma/COPD

patients and doctors

Sensor technology to

monitor patient

adherence in

Eyecare

Connected devices,

data platform and

patient management

services (China)

A global provider of

innovative electronic

drug delivery

systems and digital

services

Aptar Pharma Digital

Aptar Pharma

YTD Sept. 2020 Results

(1) Excludes acquisitions and currency effects. (2) Adjusted EBITDA (earnings before net interest, taxes,

depreciation and amortization) excludes restructuring costs,

acquisition costs, non-recurring purchase accounting adjustments.

Metric3 Year

Average

YTD

2020

Long-term

Target

Core sales growth1 10% 8% 6-10%

Adj. EBITDA2 margin 35% 36% 32-36%

16

$824

$914

$0

$200

$400

$600

$800

$1,000

YTD 2019 YTD 2020

$ in m

illio

ns

Sales

Reported

+11%

Core

8%

Acquisitions

3%

Currency

Effects

0%

36% 36%

0%

10%

20%

30%

40%

YTD 2019 YTD 2020

Adjusted EBITDA(2) Margin%

Active Material Solutions

17

Proprietary Active Polymer Technology

18

• Maintains integrity of the contents inside

• Extends shelf-life

• Controls moisture and reduces oxygen

• Removes odor

Glucose Test

Strips

Activ-Blister™ - Solution for an HIV Prevention Medicine

19

EUA Filed April 2020: Introducing ActivShield™ Solution for Virus Mitigation on N95 Masks

20

ActivShield™ is a safe and convenient way to deliver antimicrobial & antiviral treatment of N95 masks on site.

Company Financials

21

YTD 2020 Recap

• Impact of COVID-19 tracking with our

expectations from earlier this year: Q2 was

low-point, markets generally performing as

anticipated, gradual recovery in process

• Best of breed Pharma business continued to

grow device and component sales in each

market over very strong prior year

• Strong growth in Q2 and Q3 sales to the

Personal Care market partially offsetting

decreased sales to the Beauty Market

• Good growth in sales to the Food market

offsetting decreased sales to the Beverage

market

• Recent acquisitions performing well including

FusionPKG and Noble International

• Generating strong level of cash flow above

prior year levels

22

Aptar Pharma Advertisement-8%

-6%

-4%

-2%

0%

2%

4%

6%

8%

10%

Q1 Q2 Q3

Sales Growth by Quarter 2020

Reported Core

Anticipated Pandemic Impact 2020

Nine Months Year-to-Date 2020 Company Reported Results

23

YTD Highlights

• Pharma segment continues to perform

well through the first nine months of the

year with growth over a very strong

period a year ago

• Beauty + Home and Food + Beverage

segments experienced a more difficult

first nine months due to the impacts of

COVID-19

• Progressive signs of improvement for

Beauty + Home and positive results for

Food + Beverage as we moved further

into the year

• Pleased with the performance of our

recent acquisitions, in particular

FusionPKG and Noble

-2%Core Sales

Growth*

-1%Currency

Effects

+3%Acquisitions

29%YTD 2019

Reported

Effective Tax

Rate

29%YTD 2020

Reported

Effective Tax

Rate

$2,188 $2,180

$0

$500

$1,000

$1,500

$2,000

$2,500

YTD 2019 YTD 2020

Reported YTD Sales(in millions $)

0%

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.

Adjustments:

• 2019: Restructuring initiatives of $17.3 mil;

transaction costs related to acquisitions of $1.8 mil

• 2020: Restructuring initiatives of $15.6 mil;

Transaction costs related to acquisitions of $4.8

mil; Purchase accounting adjustments of $1.3 mil

* See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures.

Nine Months Year-to-Date 2020 Adjusted EPS and Adjusted EBITDA

24

29%YTD 2019Effective Tax

Rate Adjusted

Earnings*

28%YTD 2020Effective Tax

Rate Adjusted

Earnings*

YTD Adjusted EPS and

Adjusted EBITDA Highlights

• Strong Pharma results able to

compensate for COVID-related

shortfalls, especially within our

beauty and beverage applications

• Realizing temporary operating

inefficiencies in order to maintain

critical supply of product during

COVID

$461 $437

$0

$100,000

$200,000

$300,000

$400,000

$500,000

YTD 2019 YTD 2020

Adjusted YTD EBITDA(in millions $)

-5%$3.15 $2.72

$-

$1.00

$2.00

$3.00

$4.00

YTD 2019 YTD 2020

Adjusted YTD EPS*

-14%

Consolidated Financial Targets

25

Metric

3 Year

Average 2019 Q3 YTD 2020 Long-term Target

Core sales growth1 5% 3% -2% 4-7%

Adj. EBITDA2 /Sales % 20% 21% 20% 20-22%

ROIC3 13% 11% 10% 13-15%

Dividend Payout Ratio 36% 36% 40% 30-40%

Leverage Ratio ≈ 1.7X ≈ 1.7X ≈ 1.8X 1-3X

1 – Excludes acquisitions and currency effects.

2 – Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting

adjustments.

3 – Return on invested capital = adjusted earnings before net interest and taxes, less tax effect / average capital (average of beginning of year and end of year capital) [capital =

equity plus debt less cash].

4 – Cash dividends paid / adjusted earnings per share.

Key Takeaways – Aptar Pharma

26

✓Unique niche market

✓Defendable leading positions

✓Decades of experience in the

regulatory space

✓Proprietary devices and

material science (Aptar IP)

✓Growing our moat with

expanded services and

digital platforms

✓Consistent, best in class

growth and margins

2012 2013 2014 2015 2016 2017 2018 2019

Sales ($ mil) $589 $709 $751 $712 $741 $806 $955 $1,091

EBITDA Margin 30.7% 32.4% 32.8% 34.9% 35.0% 34.2% 36.0% 35.5%

30%

31%

32%

33%

34%

35%

36%

37%

$-

$200

$400

$600

$800

$1,000

$1,200

Aptar Pharma Sales and EBITDA Margin

Long-term Compounding Growth Story

27

✓Diversified model serving

attractive end-markets

✓Best in class healthcare franchise

✓Leader in beauty and food

dispensing solutions

✓ Innovation and IP driven portfolio

✓Leveraging synergies, including

technologies, across each business

✓Consistently strong balance sheet

✓ Investing in our business for future

growth

27

+4.5%CAGR

Core Sales

+8%CAGR

Adjusted

EPS

+9%CAGR

Dividend

• average yield over 10

years = 1.6%

• 27 consecutive years

of paying increased

annual dividends

Contact:

Matt DellaMariaSVP, Investor Relations & Communications

Phone: 815-479-5530Email: Matt.Dellamaria@aptar.com

28

“We transform ideas into solutions that transform lives.”